Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.

Publication Type:

Journal Article


The lancet oncology, Volume 14, Issue 10, p.999-1008 (2013)


2013, Adolescent, Adult, Child, Child, Preschool, Clinical Research Division, Disease-Free Survival, Humans, Immunomagnetic Separation, Infant, Neuroblastoma, October 2013, Peripheral Blood Stem Cell Transplantation, RISK


Myeloablative chemoradiotherapy and immunomagnetically purged autologous bone marrow transplantation has been shown to improve outcome for patients with high-risk neuroblastoma. Currently, peripheral blood stem cells (PBSC) are infused after myeloablative therapy, but the effect of purging is unknown. We did a randomised study of tumour-selective PBSC purging in stem-cell transplantation for patients with high-risk neuroblastoma.